SureNano Science Acquires GlucaPharm, Advancing Second-Generation GLP-1 Drug GEP44 with Improved Tolerability
核心洞察
SureNano Science Ltd. (搜索) has completed the acquisition of GlucaPharm Inc. (搜索), gaining access to GEP44, a novel patented peptide developed at Syracuse University that targets obesity and metabolic disease with reduced gastrointestinal side effects compared to first-generation GLP-1 (搜索) drugs.
GEP44 has demonstrated significant weight reduction and blood glucose normalization in preclinical studies without the nausea and gastrointestinal side effects commonly associated with current market leaders like Ozempic and Mounjaro.
The company plans to advance GEP44 through an IND-enabling FDA study followed by Phase I clinical trials in Australia, with key development milestones anticipated over the next six to nine months.
SureNano Science Ltd. (搜索) (CSE: SURE) (OTCQB: SURNF) has completed its acquisition of GlucaPharm Inc. (搜索), a next-generation glucagon-like peptide pharmaceutical company developing a patented therapeutic candidate designed to address obesity and metabolic disease with improved tolerability and delivery potential. The acquisition positions SureNano to transition from an enabling-technology company into a pharmaceutical value creator within one of the fastest-growing global drug markets.
Novel Second-Generation GLP-1 Candidate Shows Promise
GlucaPharm is developing GEP44, a novel, patented peptide discovered by researchers at Syracuse University. The compound has demonstrated significant weight reduction and blood glucose normalization in preclinical studies, without the nausea and gastrointestinal side effects commonly associated with first-generation GLP-1 (搜索) drugs currently on the market such as Ozempic, Wegovy, and Mounjaro.
GEP44 is exclusively licensed from Syracuse University and represents a second-generation GLP opportunity targeting comparable or superior efficacy with improved patient tolerability. The global GLP market remains in its early stages and is currently dominated by injectable, first-generation therapies such as Ozempic and Mounjaro, which have generated substantial revenues and strong market adoption.
Alternative Delivery Methods Under Development
GlucaPharm's platform focuses on advancing a differentiated GLP asset with the potential for non-injectable administration, including oral, sublingual, or nasal delivery. Management believes these alternative delivery methods could materially expand patient adoption and long-term market penetration compared to current injectable therapies.
Clinical Development Timeline and Leadership Changes
GlucaPharm is advancing GEP44 in collaboration with an experienced Australian contract research organization (CRO), with an IND-enabling FDA study followed by Phase I Clinical Trial expected to commence in Australia in the coming months. Key development milestones are anticipated over the next six to nine months, including IND progression and early clinical validation.
The company has appointed Dr. Nihar R. Pandey as Director and Chief Scientific Officer. Dr. Pandey brings over 25 years of expertise in drug discovery and development, with a Ph.D. in Clinical Biochemistry and postdoctoral training from the University of Montreal, Clinical Research Institute of Montreal, and McGill University. He previously served as a Research Scientist at the University of Ottawa Heart Institute and as Group leader for Drug Discovery and Development at Liponex Inc.
Transaction Structure and Financial Support
The acquisition was structured as a share exchange with total consideration of 8,100,999 common shares issued to GlucaPharm shareholders and warrants to purchase 5,000,000 common shares issued to GlucaPharm warrant holders. The shares are subject to hold period restrictions until approval of SureNano's 2026 Annual Form 5A and release of 2026 annual audited financial statements.
SureNano recently completed $1.25 million in financing, including warrants exercisable at $0.35, intended to support near-term development and subsequent funding rounds. The combined company is supported by a management team with demonstrated experience in drug discovery, obesity and diabetes research, FDA regulatory pathways, and capital markets.
"This acquisition marks a transformational milestone for SureNano," said Charles MaLette, CEO of SureNano Science Ltd. (搜索) "GlucaPharm provides the Company with a highly differentiated GLP asset at a time when demand for effective, better-tolerated metabolic therapies continues to accelerate globally. With an experienced development team, a clear FDA pathway, and strong institutional support, we believe GEP44 positions SureNano to participate meaningfully in one of the most significant pharmaceutical markets of the decade."
As GEP44 advances through IND, Phase I, and Phase II-III development towards FDA approval, management expects SureNano to be positioned as one of the only micro-cap public companies developing GLP technology, with direct exposure to the multi-hundred-billion-dollar GLP-1 (搜索) metabolic market, and the potential to compete alongside large pharmaceutical incumbents, based on current preclinical results.